Our study demonstrated that BRD7 promotes CRC progression through stabilizing the c-Myc protein and protecting it from ubiquitin–proteasome-mediated degradation and that BRD7 functions as a promising prognostic factor and a potential therapeutic target for CRC. Here, BRD7 is linked to colorectal carcinoma.